Allos AI today announced $5 million in seed financing led by Oxford Science Enterprises (OSE) to commercialize the industry's first "glass-box" Causal AI platform, accelerating the end-to-end ...

Oncologic drug development needs to place a greater focus on the patient, according to a commentary in the current issue of the New England Journal of Medicine. Even though the US Food and Drug ...

Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...

FORT DETRICK, Md. – As drug developers rely increasingly on artificial intelligence to assist with the discovery, testing and manufacture of new medicines, researchers at the Defense Health Agency ...

Yoo Chang-ho, head of strategy at SK Biopharmaceuticals, left, and Bae Min-seok, CEO of PhnyX Lab, pose for a commemorative photo marking the signing of a memorandum of understanding on AI-based drug ...

In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work ...